Trial Profile

A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia.

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 23 Mar 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eszopiclone (Primary) ; Zolpidem
Indications Insomnia
Focus Registrational; Therapeutic Use

Most Recent Events

18 Jan 2012 Results were presented in an Eisai media release.
30 Nov 2010 A Marketing Authorization Application has been submitted in Japan based on the results from this study.
21 Sep 2010 Assumed completed; checked with ms1.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com